BioMarin Pharmaceutical Inc. $BMRN Shares Sold by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. lessened its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 50.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 25,167 shares of the biotechnology company’s stock after selling 25,586 shares during the quarter. Envestnet Asset Management Inc.’s holdings in BioMarin Pharmaceutical were worth $1,363,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in BMRN. Financiere des Professionnels Fonds d investissement inc. purchased a new position in shares of BioMarin Pharmaceutical during the third quarter worth $1,047,000. Jump Financial LLC boosted its holdings in BioMarin Pharmaceutical by 530.3% during the 2nd quarter. Jump Financial LLC now owns 291,217 shares of the biotechnology company’s stock valued at $16,008,000 after acquiring an additional 245,017 shares during the period. AQR Capital Management LLC grew its position in BioMarin Pharmaceutical by 90.7% in the 2nd quarter. AQR Capital Management LLC now owns 5,580,573 shares of the biotechnology company’s stock valued at $306,429,000 after acquiring an additional 2,654,768 shares in the last quarter. Federated Hermes Inc. grew its position in BioMarin Pharmaceutical by 292.6% in the 3rd quarter. Federated Hermes Inc. now owns 278,315 shares of the biotechnology company’s stock valued at $15,074,000 after acquiring an additional 207,430 shares in the last quarter. Finally, Mediolanum International Funds Ltd increased its stake in BioMarin Pharmaceutical by 56.2% during the third quarter. Mediolanum International Funds Ltd now owns 137,675 shares of the biotechnology company’s stock worth $7,437,000 after purchasing an additional 49,534 shares during the period. Hedge funds and other institutional investors own 98.71% of the company’s stock.

Key Headlines Impacting BioMarin Pharmaceutical

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Sanford C. Bernstein published a bullish forecast calling for strong price appreciation for BMRN, which can lift investor expectations ahead of upcoming catalysts. Sanford C. Bernstein Forecast
• Positive Sentiment: Wells Fargo flagged BMRN as an attractive buy ahead of the Transcon‑CNP PDUFA decision, highlighting regulatory upside as a near‑term positive catalyst. Wells Fargo note
• Neutral Sentiment: Coverage pieces analyzing recent share rebound and DCF upside present valuation arguments but offer no clear catalyst; useful for investors modeling scenarios but not an immediate price driver. Valuation/DCF analysis
• Neutral Sentiment: Reported short‑interest data is effectively zero and contains apparent data errors (showing increases of “NaN”); this appears to be a reporting glitch and does not signal a meaningful short squeeze or surge in bearish positioning. (data entries dated Feb 26–27)
• Negative Sentiment: EVP Gregory Friberg sold 6,326 shares for roughly $382k at an average $60.38 on Feb. 26 — an insider sale that can weigh on sentiment, especially given the size relative to his remaining stake. Insider sale filing
• Negative Sentiment: HC Wainwright published a pessimistic forecast for BMRN, which could pressure sentiment among more risk‑sensitive investors. HC Wainwright note
• Negative Sentiment: Oppenheimer lowered its price target to $95, a cut that may temper upside expectations despite other bullish targets — contributes to mixed analyst messaging. Oppenheimer target cut

Insider Transactions at BioMarin Pharmaceutical

In other BioMarin Pharmaceutical news, EVP Gregory R. Friberg sold 6,326 shares of the stock in a transaction that occurred on Thursday, February 26th. The shares were sold at an average price of $60.38, for a total value of $381,963.88. Following the transaction, the executive vice president directly owned 37,578 shares in the company, valued at $2,268,959.64. This represents a 14.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.85% of the stock is owned by company insiders.

BioMarin Pharmaceutical Trading Up 1.0%

NASDAQ:BMRN opened at $61.73 on Monday. BioMarin Pharmaceutical Inc. has a 1 year low of $50.76 and a 1 year high of $73.51. The stock has a market cap of $11.87 billion, a P/E ratio of 34.68, a P/E/G ratio of 0.54 and a beta of 0.25. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.50 and a current ratio of 5.21. The stock has a 50-day simple moving average of $58.91 and a 200-day simple moving average of $56.17.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on BMRN shares. Truist Financial lifted their price objective on shares of BioMarin Pharmaceutical from $80.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday, December 23rd. Canaccord Genuity Group boosted their price target on shares of BioMarin Pharmaceutical from $98.00 to $104.00 and gave the stock a “buy” rating in a research note on Thursday. Leerink Partners cut BioMarin Pharmaceutical from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $82.00 to $60.00 in a research note on Wednesday, December 3rd. Sanford C. Bernstein lifted their target price on BioMarin Pharmaceutical from $90.00 to $94.00 and gave the company an “outperform” rating in a report on Wednesday, February 25th. Finally, Stifel Nicolaus set a $68.00 target price on BioMarin Pharmaceutical in a research note on Tuesday, February 24th. Fifteen analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $87.71.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.